知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 数据来源：国家统计局，智研咨询整理 上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2025-2031年中国医药制造行业市场发展态势及前景战略研判报告》 2025年上半年，医药制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从2011年起，规模 以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为9800个， 和上年同期相比，增加了140个，同比增长1.45%，占工业总企业的比重为1.88%。 ...

Market Performance - The three major A-share indices showed mixed results, with the Shanghai Composite Index up by 0.53%, the Shenzhen Component Index up by 0.14%, and the ChiNext Index down by 0.26% [2] - The North China 50 Index increased by 0.18%, and the total trading volume in the Shanghai and Shenzhen markets reached 101.86 billion yuan, an increase of 8.6 billion yuan compared to the previous day [2] - Over 3,300 stocks in the market experienced gains [2] Sector Performance - The PEEK materials sector, military equipment restructuring, and photolithography machine sectors saw significant gains, while the pharmaceutical sector underwent adjustments [2] - PEEK materials showed strong performance across the board, with Zhongxin Fluorine Materials hitting the daily limit, and companies like Xinhan New Materials, Huami New Materials, and Nanjing Julong rising over 10% [2] - The military equipment restructuring concept experienced fluctuations, with Great Wall Military Industry reaching the daily limit [2] - The photolithography machine sector also performed well, with Zhangjiang Hi-Tech hitting the daily limit [2] - The pharmaceutical sector faced collective adjustments, with Qizheng Tibetan Medicine hitting the daily limit down, and companies like Anglikang and Nanjing New Medicine dropping over 9% [2]

三大指数涨跌不一，截至午盘，沪指涨0.53%，深成指涨0.14%，创业板指跌0.26%，北证50指数涨 0.18%，沪深京三市半日成交额10186亿元，较上日放量860亿元。全市场超3300只个股上涨。板块题材 上，PEEK材料、兵装重组、光刻机板块走高，医药板块调整。盘面上，PEEK材料全线走强，中欣氟材 涨停封板，新瀚新材、华密新材、南京聚隆涨超10%。兵装重组概念冲高震荡，长城军工涨停封板。光 刻机板块走高，张江高科触及涨停。医药板块集体调整，奇正藏药跌停封板，昂利康、南新制药跌超 9%。 ...

每周行业比较 - 市场回调后，应该选哪些方向？ 20250804 上周资本市场情绪回落，万德全 A 市盈率小幅下降，成长股表现优于其 他板块，医药、通信等行业收涨。价值稳定风格有所改善，但多数行业 回调，有色金属、煤炭等与地产链及周期品相关板块回调较多。 上周港股大幅回调，恒生指数和恒生科技指数均显著下行，原材料板块 跌幅最大，与反内卷预期回落相关。全球主要商品（除能源外）也出现 不同程度的回调，受国内反内卷政策及海外美国经济数据承压影响。 未来重点关注外卖平台补贴力度回落后的盈利改善情况，以及资本市场 情绪变化和各行业表现。在反内卷政策背景下，高质量发展和全国统一 大市场建设将成为重要主题。 世界人工智能大会有哪些重要内容？对行业有何影响？ 世界人工智能大会于 7 月 26 日至 28 日在上海举办，会展面积首次超过 7 万平 方米，吸引了多家企业参展，共展示 3,000 余项前沿科技，其中中国首发首秀 约 100 余项。李强总理出席开幕式并发表主题演讲，强调三点：普惠、创新与 合作、共同治理。这次大会发布了全球治理行动方案，包括 13 条促进人工智 能发展的计划，并在闭幕式上发布了上海市进一步扩大人工智能 ...

Core Insights - The 2025 Fortune China 500 list features 21 companies from Guangzhou, with 2 new entrants and 19 returning companies, primarily in energy, automotive, pharmaceuticals, and technology sectors [2][3] - 61.9% of the listed companies from Guangzhou saw an increase in their rankings, with significant rises in the technology and finance sectors [2][4] Company Performance - China Southern Power Grid maintained its position at 25th with revenue of 118.61 billion [3] - Guangzhou Automobile Group ranked 66th with revenue of 56.06 billion, up 13 places from last year [3] - Xpeng Motors achieved a remarkable ranking increase of 101 places, now at 351st, with a revenue growth of 31.1% [6] - New entrant Guangzhou Rural Commercial Bank ranked 354th, rising over 156 places from outside the list [2][3] Sector Highlights - In the new materials sector, Kingfa Technology reported a revenue increase of 24.2%, ranking up 50 places, driven by innovations in high-performance materials [4] - In the technology finance sector, GF Securities rose 63 places, while Guangzhou Industrial Investment ranked up 38 places, focusing on investments in key industries [4] Innovation and Technology - Xpeng Motors is leading in technological innovation with its self-developed smart driving systems and plans for a flying car production base [6][7] - Daclin Pharmacy, as a new entrant, is leveraging digital transformation in pharmaceutical services, enhancing efficiency through AI and big data [5] Future Outlook - The ongoing development of the Guangdong-Hong Kong-Macao Greater Bay Area is expected to further enhance Guangzhou's position as a technology innovation hub, with companies transitioning from potential to leadership roles in their respective fields [5]

Group 1 - The company holds a 45% stake in Shandong Shengli Biological Engineering Co., Ltd. [1] - Shandong Shengli belongs to the pharmaceutical manufacturing industry [1] - The company primarily utilizes biological fermentation technology to produce animal-specific antibiotic raw materials, formulations, and feed additives [1] - The products are mainly applied to terrestrial and aquatic animals [1]

Core Points - The sixth National Excellent Builders of Socialism with Chinese Characteristics award ceremony was held, with Xu Haoyu, Chairman and President of Yangtze River Pharmaceutical Group, among the 100 honorees [1] - The selection was organized by multiple government departments to inspire non-public economic figures to contribute to national development and health needs [1] - Yangtze River Pharmaceutical Group aims to integrate its development into national strategies and focus on high-quality growth in the pharmaceutical and health industry [1] Group 1 - Yangtze River Pharmaceutical Group's health sector and international business saw significant sales growth in the first half of the year, with increases of 365% and 237% respectively, becoming a "second growth curve" for the company [2] - The company achieved a seven-star certification in the EFQM Global Award's first phase, marking it as the only pharmaceutical enterprise in China to do so [2] - The company was recognized as one of the first excellent smart factories in the country, enhancing its status in intelligent manufacturing [2] Group 2 - Yangtze River Pharmaceutical Group has made substantial contributions to social responsibility, donating over 1 billion RMB in various charitable activities, and has received accolades for its efforts [3] - The company promotes health awareness and traditional Chinese medicine culture through its brand matrix, which includes "Yangtze River" Western medicine, "Longfengtang" Chinese medicine, and "Huyou" health products [2] - As a leader in the industry, the company fosters collaborative innovation across the supply chain and has established platforms for the health industry ecosystem [2]

Group 1 - As of August 4, 2025, Zhongheng Group's stock price is 2.74 yuan, down 0.02 yuan or 0.72% from the previous trading day [1] - The trading volume for the day was 616,400 hands, with a total transaction amount of 166.7 million yuan [1] - Zhongheng Group primarily engages in pharmaceutical manufacturing, with core products including thrombolytic agents for cardiovascular diseases [1] Group 2 - The company has a wholly-owned subsidiary, Zhongheng Innovation, which acquired a patent for a drug treating chronic heart failure for 55 million yuan [1] - This drug is a novel compound discovered by the Navy Medical University, significantly enhancing myocardial energy metabolism, and currently, there are no similar drugs on the market globally [1] - The company operates in various sectors, including pharmaceutical manufacturing, research and development, and health food, making it a key player in the Guangxi region [1]

证券代码：301263 证券简称：泰恩康 公告编号：2025-051 广东泰恩康医药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》及《广东泰恩康医药股份有限公司章程》 （以 下简称"《公司章程》"）的规定，广东泰恩康医药股份有限公司（以下简称"公 司"）于 2025 年 8 月 4 日召开第五届董事会第九次会议审议通过《关于召开公司 召开 2025 年第一次临时股东大会。现将本次会议有关事项通知如下： 一、召开会议的基本情况 （1）公司第五届董事会第九次会议于 2025 年 8 月 4 日召开，审议通过《关 于召开公司 2025 年第一次临时股东大会的议案》。 （2）本次股东大会会议召集程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 （1）现场会议时间：2025 年 8 月 20 日（星期三）下午 15:00。 （2）网络投票时间：其中，通过深圳证券交易所（以下简称"深交所"） 交易系统进行网络投票的具体时间为：2025 年 8 月 20 日 9:15-9:25、9:30-11:30， （1 ...

Core Viewpoint - 泰恩康 is set to hold an investor meeting on August 4, 2025, with participation from its chairman and general manager, Zheng Hanjie, to address investor inquiries [2]. Company Overview - For the year 2024, 泰恩康's revenue composition is as follows: - Pharmaceutical agency accounts for 61.1% - Pharmaceutical manufacturing accounts for 37.28% - Pharmaceutical technology services account for 1.51% - Other businesses account for 0.12% [2].